Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
- Dimopoulos, M.A.
- Richardson, P.G.
- Bahlis, N.J.
- Grosicki, S.
- Cavo, M.
- Beksaç, M.
- Legieć, W.
- Liberati, A.M.
- Goldschmidt, H.
- Belch, A.
- Magen, H.
- Larocca, A.
- Laubach, J.P.
- Petrucci, M.T.
- Reece, D.
- White, D.
- Mateos, M.-V.
- Špička, I.
- Lazaroiu, M.
- Berdeja, J.
- Kaufman, J.L.
- Jou, Y.-M.
- Ganetsky, A.
- Popa McKiver, M.
- Lonial, S.
- Weisel, K.
- Erakutsi egile guztiak +
ISSN: 2352-3026
Argitalpen urtea: 2022
Alea: 9
Zenbakia: 6
Orrialdeak: e403-e414
Mota: Artikulua